EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Tumor desialylation surpasses anti‐ PD ‐ L1 checkpoint therapy in restoring anti‐tumor immunity in a murine model for colorectal cancer

Irene van der Haar Àvila, Tao Zhang, Victor Lorrain, Eelco Keuning, Laraib Amir Ali, Cora Chadick, Sara García-García, Louis Boon, Noortje de Haan, Juan J García-Vallejo, Yvette van Kooyk, Sandra J van Vliet

International Journal of Cancer · 2025-11 · 157 (9) · 1948-1962

DOI: 10.1002/ijc.70031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 07.07.2025. Verfasst von Irene van der Haar Àvila und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors, B7-H1 Antigen, N-Acetylneuraminic Acid. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: KWF Kankerbestrijding, EU HORIZON-CSA, Health~Holland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abnormal levels of tumor‐associated glycans are correlated with tumor progression in many types of cancer, including (CRC). Sialic acids, a family of nine‐carbon monosaccharides, are key regulators of the anti‐tumor immune response via Siglecs, yet the sialic acid‐specific effects are highly dependent on the tumor type studied. Therefore, a detailed understanding of sialic acid‐mediated immunomodulation in different tumor contexts is warranted. Using CRISPR/Cas9 technology, we generated an isogenic knockout of the N ‐acylneuraminate cytidylyltransferase ( Cmas ) gene in CT26 CRC cells, thus creating cells that lack cell surface sialylation. Compared to CT26‐MOCK control cells, CT26‐CMAS KO cells displayed significantly reduced tumor growth in vivo , resulting in increased survival of the mice. This difference was absent in immunodeficient mice, signifying an immune‐dependent effect. High‐dimensional profiling of immune cell networks in the tumor microenvironment revealed increased infiltration and differentiation trajectories of lymphoid cells in the CT26‐CMAS KO tumors, especially of natural killer (NK) cells and γδ T cells. Strikingly, sialic acid ablation resulted in a stronger immunostimulatory capacity and did not synergize with anti‐PD‐L1 checkpoint inhibition, suggesting that at least in the CT26 model, sialic acids impose a superior immune inhibitory circuit than the well‐known PD‐1/PD‐L1 pathway. Overall, our findings strengthen the concept of sialic acid‐mediated impairment of tumor immune surveillance and reinforce ongoing efforts to target sialic acids for the treatment of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmune Checkpoint InhibitorsB7-H1 AntigenN-Acetylneuraminic AcidAnimalsMiceTumor MicroenvironmentHumansCell Line, TumorDisease Models, AnimalNucleotidyltransferasesFemaleMice, Knockout

Stichwörter der Autor:innen

anti‐tumor immunitycolorectal cancerimmune checkpoint therapysialylation

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenN-Acetylneuraminic AcidNucleotidyltransferasesCd274 protein, mouse

Autor:innen und Institutionen

  • Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Institute for Immunology and Infectious Diseases, Cancer Immunology, Amsterdam, The Netherlands.
  • Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • JJP Biologics, Warsaw, Poland.

Förderung

  • KWF Kankerbestrijding
  • EU HORIZON-CSA
  • Health~Holland

Zitieren

APA

van der Haar Àvila, I., Zhang, T., Lorrain, V., Keuning, E., Ali, L. A., Chadick, C., García-García, S., Boon, L., de Haan, N., García-Vallejo, J. J., van Kooyk, Y., & van Vliet, S. J. (2025). Tumor desialylation surpasses anti‐ PD ‐ L1 checkpoint therapy in restoring anti‐tumor immunity in a murine model for colorectal cancer. International Journal of Cancer, 157(9), 1948-1962. https://doi.org/10.1002/ijc.70031

Vancouver

van der Haar Àvila I, Zhang T, Lorrain V, Keuning E, Ali LA, Chadick C, et al. Tumor desialylation surpasses anti‐ PD ‐ L1 checkpoint therapy in restoring anti‐tumor immunity in a murine model for colorectal cancer. International Journal of Cancer. 2025;157(9):1948-1962. doi:10.1002/ijc.70031

BibTeX
@article{vanderHaarvila2025,
  author = {van der Haar Àvila, Irene and Zhang, Tao and Lorrain, Victor and Keuning, Eelco and Ali, Laraib Amir and Chadick, Cora and García-García, Sara and Boon, Louis and de Haan, Noortje and García-Vallejo, Juan J and van Kooyk, Yvette and van Vliet, Sandra J},
  title = {Tumor desialylation surpasses anti‐ PD ‐ L1 checkpoint therapy in restoring anti‐tumor immunity in a murine model for colorectal cancer},
  journal = {International Journal of Cancer},
  year = {2025},
  volume = {157},
  number = {9},
  pages = {1948--1962},
  doi = {10.1002/ijc.70031}
}
Kostenlos starten →